Free Trial

Cue Biopharma (CUE) Competitors

Cue Biopharma logo
$1.61
-0.14 (-8.00%)
(As of 10/31/2024 ET)

CUE vs. AVIR, URGN, STRO, BTMD, PRQR, HRTX, IMMP, GNFT, CDXC, and EDIT

Should you be buying Cue Biopharma stock or one of its competitors? The main competitors of Cue Biopharma include Atea Pharmaceuticals (AVIR), UroGen Pharma (URGN), Sutro Biopharma (STRO), biote (BTMD), ProQR Therapeutics (PRQR), Heron Therapeutics (HRTX), Immutep (IMMP), Genfit (GNFT), ChromaDex (CDXC), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

Cue Biopharma vs.

Cue Biopharma (NASDAQ:CUE) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, community ranking, media sentiment and earnings.

Cue Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 210.56%. Atea Pharmaceuticals has a consensus target price of $6.88, indicating a potential upside of 112.35%. Given Cue Biopharma's higher possible upside, equities research analysts plainly believe Cue Biopharma is more favorable than Atea Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Atea Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
3.00

35.0% of Cue Biopharma shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 7.5% of Cue Biopharma shares are owned by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cue Biopharma and Cue Biopharma both had 2 articles in the media. Cue Biopharma's average media sentiment score of 1.58 beat Atea Pharmaceuticals' score of 0.96 indicating that Cue Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cue Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Atea Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Cue Biopharma has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.

Cue Biopharma has higher earnings, but lower revenue than Atea Pharmaceuticals. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Cue Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cue Biopharma$8.30M9.44-$50.73M-$1.06-1.52
Atea Pharmaceuticals$351.37M0.78-$135.96M-$2.10-1.54

Cue Biopharma received 128 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 52.33% of users gave Cue Biopharma an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Cue BiopharmaOutperform Votes
146
52.33%
Underperform Votes
133
47.67%
Atea PharmaceuticalsOutperform Votes
18
47.37%
Underperform Votes
20
52.63%

Atea Pharmaceuticals has a net margin of 0.00% compared to Cue Biopharma's net margin of -566.02%. Atea Pharmaceuticals' return on equity of -33.24% beat Cue Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Cue Biopharma-566.02% -142.93% -82.85%
Atea Pharmaceuticals N/A -33.24%-31.06%

Summary

Cue Biopharma beats Atea Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CUE vs. The Competition

MetricCue BiopharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$78.32M$7.12B$5.36B$8.41B
Dividend YieldN/A8.77%5.22%4.20%
P/E Ratio-1.6616.06131.9317.57
Price / Sales9.44258.281,440.1578.36
Price / CashN/A50.1639.0633.56
Price / Book1.965.674.744.57
Net Income-$50.73M$151.16M$115.43M$225.42M
7 Day Performance3.21%-1.80%-0.86%-0.61%
1 Month Performance112.63%5.92%3.61%1.50%
1 Year Performance-23.33%39.97%38.90%32.94%

Cue Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CUE
Cue Biopharma
4.6209 of 5 stars
$1.61
-8.0%
$5.00
+210.6%
-8.9%$78.32M$8.30M-1.6660Positive News
AVIR
Atea Pharmaceuticals
3.753 of 5 stars
$3.35
-0.9%
$6.88
+105.4%
+5.8%$284.67M$351.37M-1.6070Short Interest ↓
URGN
UroGen Pharma
4.2565 of 5 stars
$12.10
flat
$48.38
+299.8%
+19.8%$283.79M$85.01M-3.69200Upcoming Earnings
Positive News
STRO
Sutro Biopharma
4.0521 of 5 stars
$3.45
-0.3%
$12.13
+251.4%
+38.0%$282.19M$169.36M-1.89240
BTMD
biote
3.9797 of 5 stars
$5.13
+2.2%
$8.39
+63.5%
-2.1%$281.94M$185.36M30.18194Short Interest ↓
News Coverage
Positive News
PRQR
ProQR Therapeutics
2.8373 of 5 stars
$3.46
+0.3%
$3.38
-2.5%
+205.0%$281.49M$15.41M-11.93180Upcoming Earnings
Analyst Upgrade
HRTX
Heron Therapeutics
3.653 of 5 stars
$1.85
+3.9%
$6.00
+224.3%
+185.7%$278.71M$136.36M-5.78300Positive News
IMMP
Immutep
1.3228 of 5 stars
$1.90
+0.5%
$8.00
+321.1%
+6.6%$276.37M$5.14M0.002,021Positive News
GNFT
Genfit
1.4651 of 5 stars
$5.50
-1.6%
$13.00
+136.4%
+86.9%$274.48M$76.06M0.00120Short Interest ↑
News Coverage
CDXC
ChromaDex
4.3663 of 5 stars
$3.47
+1.2%
$6.00
+72.9%
+171.2%$262.12M$85.58M-173.50106Short Interest ↓
News Coverage
EDIT
Editas Medicine
4.6615 of 5 stars
$3.18
flat
$9.91
+211.6%
-52.3%$261.52M$67.03M-1.35230Upcoming Earnings
Short Interest ↑
Analyst Revision

Related Companies and Tools


This page (NASDAQ:CUE) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners